Study title: Double~blind, bicenter, randomized, crossover study to prove equivalent efficacy and tolerance of Creon® 25 000 Minimicrospheres™ versus Creon® 25 000 Microspheres (Pankreon® forte) in patients with pancreatic exocrine insufficiency caused by cystic fibrosis.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Digestive System Diseases | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: Pancreatin | |||||
ATC code: | |||||
Document link: Pancreatin-S248-3002.pdf | |||||
Document date: 2011-10-19 | |||||
Study number: S248-3002 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |